Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Cancer Vaccines01:30

Cancer Vaccines

960
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
960
Vaccinations01:51

Vaccinations

51.2K
Overview
51.2K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

6.5K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
6.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lenalidomide boosts CD1d-Vδ2 bispecific antibody-engaged Vγ9Vδ2-T cell effector functions via CD28, Notch signaling and IL-2 release.

Journal for immunotherapy of cancer·2026
Same author

Rescue by radiotherapy and anti-CTLA4/PD-1 after failure of anti-PD-1 therapy in patients with metastatic NSCLC: the phase II RECLAIM trial.

Journal for immunotherapy of cancer·2026
Same author

The survival impact of combining radiotherapy and immune checkpoint inhibitors in patients with solid tumors: A systematic review and living meta-analysis of randomized controlled trials.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Local immunotherapy in the neoadjuvant treatment of cancer: optimizing efficacy while limiting toxicity?

Journal for immunotherapy of cancer·2026
Same author

Local immunotherapy for the treatment of cancer: scientific advances and clinical potential.

Journal for immunotherapy of cancer·2026
Same author

Sex-based considerations in the choice for a TLR9 or TLR7/8 agonist to arm the sentinel lymph node in early-stage melanoma.

Oncoimmunology·2026

Related Experiment Video

Updated: Jan 15, 2026

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
08:40

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

18.6K

Dendritic cell immunotherapy advances for solid tumors: Vaccination and modulation.

Georgia Clayton1, Elisa C Toffoli2, Tanja D de Gruijl2

  • 1Department of Molecular Cell Biology and Immunology, Amsterdam UMC, Vrije Universiteit Amsterdam, 1081 HV Amsterdam, the Netherlands; Cancer Immunology, Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands.

Cell Reports. Medicine
|October 14, 2025
PubMed
Summary

Dendritic cell (DC) immunotherapy shows promise for cancer treatment by enhancing anti-tumor immunity. Ongoing research focuses on overcoming challenges in the tumor microenvironment to improve clinical benefits for patients.

Keywords:
dendritic cellstherapiestumor microenvironmentvaccination

More Related Videos

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.9K
Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

1.5K

Related Experiment Videos

Last Updated: Jan 15, 2026

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
08:40

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

18.6K
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.9K
Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

1.5K

Area of Science:

  • Immunology
  • Oncology
  • Cancer Immunotherapy

Background:

  • Dendritic cells (DCs) are crucial antigen-presenting cells that initiate anti-tumoral immune responses.
  • The tumor microenvironment (TME) often contains immunosuppressive signals that impair DC function, limiting anti-cancer immunity.
  • DC-based immunotherapy aims to restore or enhance anti-tumor functions of DCs.

Purpose of the Study:

  • To provide an updated review of novel dendritic cell (DC) immunotherapy strategies.
  • To identify trends associated with successful outcomes in DC-based cancer therapies.
  • To highlight the challenges that remain in the field of DC immunotherapy.

Main Methods:

  • Review of recent clinical trials and research advancements in DC immunotherapy.
  • Analysis of the complex interactions within the tumor microenvironment (TME).
  • Identification of emerging technologies and strategies for enhancing DC function.

Main Results:

  • Despite decades of research, clinical benefits of DC immunotherapy are often limited.
  • Novel DC immunotherapy strategies are continuously emerging and entering clinical trials.
  • Understanding TME dynamics is key to improving DC-based cancer treatments.

Conclusions:

  • Advancements in understanding the TME and new technologies are driving innovation in DC immunotherapy.
  • Further research is needed to overcome immunosuppressive factors and enhance DC efficacy for improved patient outcomes.
  • Continued clinical investigation of novel DC-based strategies is essential for progress in cancer immunotherapy.